FINWIRES · TerminalLIVE
FINWIRES

Raymond James Initiates Coverage on MapLight Therapeutics With Strong Buy Rating

By

MapLight Therapeutics, Inc. (MPLT) has an average rating of Buy and mean price target of $39.55, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Raymond James Initiates Coverage on MapLight Therapeutics With Strong Buy Rating | FINWIRES